Patient characteristics at the start of the study for all subjects and when first entering as anti-TNF exposed and not exposed respectively
| Variables | All (n = 1430) | At entry to the study | |||||
|---|---|---|---|---|---|---|---|
| Anti-TNF exposed (n = 921) | Not anti-TNF exposed (n = 652) | ||||||
| All | Men (n = 211) | Women (n = 710) | All | Men (n = 178) | Women (n = 474) | ||
| COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; TNF, tumour necrosis factor; VAS, visual analogue scale. | |||||||
| Results are presented as means (SD) unless otherwise mentioned. | |||||||
| Age | 57.8 (13.3) | 55.1 (12.8) | 57.3 (11.5) | 54.4 (13.0) | 61.1 (13.0) | 62.5 (11.8) | 60.5 (13.4) |
| Female (n, %) | 1067 (74.6) | 710 (77.1) | — | — | 474 (72.7) | — | — |
| HAQ (score limit 0–3) | 1.28 (0.72) | 1.45 (0.63) | 1.20 (0.60) | 1.53 (0.62) | 1.12 (0.79) | 0.87 (0.74) | 1.22 (0.78) |
| VAS patient global assessment | 54.1 (26.3) | 63.4 (21.5) | 58.6 (23.1) | 64.7 (20.9) | 43.1 (27.6) | 39.5 (27.4) | 44.5 (27.6) |
| VAS pain | 54.2 (26.5) | 62.5 (22.1) | 57.7 (24.0) | 63.9 (21.1) | 45.0 (28.6) | 39.8 (29.2) | 46.9 (28.1) |
| Disease duration (years) | 13.2 (11.3) | 12.7 (9.6) | 12.3 (9.6) | 12.9 (10.0) | 14.6 (12.6) | 14.0 (12.6) | 14.8 (12.8) |
| Present prednisolone treatment (n, %) | 696 (48.7) | 646 (70.1) | 159 (75.4) | 487 (68.6) | 140 (21.5) | 41 (23.0) | 99 (20.9) |
| Previous DMARD treatment (number of drugs) | 2.8 (1.9) | 3.6 (2.0) | 3.2 (1.6) | 3.7 (2.0) | 2,2 (1.7) | 1.8 (1.5) | 2.3 (1.8) |
| Comorbidity before first visit | |||||||
| COPD (n, %) | 20 (1.4) | 13 (1.4) | 3 (1.4) | 10 (1.4) | 8 (1.2) | 6 (3.4) | 2 (0.4) |
| Diabetes (n, %) | 51 (3.6) | 40 (4.3) | 15 (7.1) | 25 (3.5) | 14 (2.1) | 6 (3.4) | 8 (1.7) |
| CVD (n, %) | 105 (7.3) | 59 (6.4) | 27 (12.8) | 32 (4.5) | 54 (8.2) | 23 (12.9) | 31 (6.5) |
| Any of the comorbidities | 154 (10.8) | 94 (10.2) | 37 (17.5) | 57 (8.0) | 71 (10.9) | 31 (17.4) | 40 (8.4) |